|
|
Volumn 4, Issue 9, 2003, Pages 831-834
|
|
Less is more. Research into anti-angiogenic therapies for treating cancer has finally had its first breakthroughs. But it may also influence the way in which classical chemotherapy is used for cancer treatment
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 (8 HYDROXY 6 METHOXY 1 OXO 1H 2 BENZOPYRAN 3 YL)PROPIONIC ACID;
2 METHOXYESTRADIOL;
2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID;
6 FLUORO 1 METHYL 4 OXO 7 (1 PIPERAZINYL) 4H 1,3 THIAZETO[3,2 A]QUINOLINE 3 CARBOXYLIC ACID;
ALPHA INTERFERON;
ANGIOGENESIS INHIBITOR;
ANGIOSTATIN;
ANTITHROMBIN III;
BEVACIZUMAB;
CANSTATIN;
CELECOXIB;
CETUXIMAB;
COMBRETASTATIN;
CYCLOPHOSPHAMIDE;
ENDOSTATIN;
ERLOTINIB;
FUMAGILLOL CHLOROACETYLCARBAMATE;
GEFITINIB;
GRANULOCYTE COLONY STIMULATING FACTOR;
MONOCLONAL ANTIBODY LM 609;
PACLITAXEL;
PIGMENT EPITHELIUM DERIVED FACTOR;
ROSIGLITAZONE;
SEMAXANIB;
TETRAHYDROCORTISOL;
THALIDOMIDE;
THROMBOSPONDIN;
TRASTUZUMAB;
TUMSTATIN;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VASCULOTROPIN;
VATALANIB;
ZOLEDRONIC ACID;
AFLIBERCEPT;
ANTITHROMBIN;
BORTEZOMIB;
ETARACIZUMAB;
THROMBOSTATIN;
ARTICLE;
CANCER CHEMOTHERAPY;
CANCER RESEARCH;
DRUG DELIVERY SYSTEM;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG SAFETY;
HUMAN;
MULTIDRUG RESISTANCE;
NONHUMAN;
PATIENT CARE;
PRIORITY JOURNAL;
STEM CELL TRANSPLANTATION;
TUMOR VASCULARIZATION;
NEOPLASM;
NEOVASCULARIZATION (PATHOLOGY);
ANTIANGIOGENIC ACTIVITY;
ANTIANGIOGENIC THERAPY;
ANTINEOPLASTIC ACTIVITY;
CANCER CELL;
CANCER RESISTANCE;
CANCER SURVIVAL;
CHILDHOOD CANCER;
LIVER CANCER;
MEDICAL RESEARCH;
METASTATIC COLORECTAL CANCER;
OVERALL SURVIVAL;
PANCREAS CANCER;
PHASE 3 CLINICAL TRIAL (TOPIC);
RANDOMIZED CONTROLLED TRIAL (TOPIC);
ANGIOGENESIS INHIBITORS;
HUMANS;
NEOPLASMS;
NEOVASCULARIZATION, PATHOLOGIC;
|
|
EID: 2342565251
PISSN: 1469221X
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.embor.embor934 Document Type: Article |
|
Times cited : (5)
|
|
References (4)
|
